These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34050373)

  • 1. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
    Petrides PE; Klein M; Schuhmann E; Torkler H; Molitor B; Loehr C; Obermeier Z; Beykirch MK
    Ann Hematol; 2021 Jul; 100(7):1685-1693. PubMed ID: 34050373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
    To-Figueras J; Wijngaard R; García-Villoria J; Aarsand AK; Aguilera P; Deulofeu R; Brunet M; Gómez-Gómez À; Pozo OJ; Sandberg S
    J Inherit Metab Dis; 2021 Jul; 44(4):961-971. PubMed ID: 33861472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Givosiran: A Review in Acute Hepatic Porphyria.
    Syed YY
    Drugs; 2021 May; 81(7):841-848. PubMed ID: 33871817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
    Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
    N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
    de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Givosiran in acute intermittent porphyria: A personalized medicine approach.
    Poli A; Schmitt C; Moulouel B; Mirmiran A; Talbi N; Rivière S; Cerutti D; Bouchoule I; Faivre A; Grobost V; Douillard C; Duchêne F; Fiorentino V; Dupré T; Manceau H; Peoc'h K; Puy H; Lefebvre T; Gouya L
    Mol Genet Metab; 2022 Mar; 135(3):206-214. PubMed ID: 35058124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
    Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
    N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute intermittent porphyria, givosiran, and homocysteine.
    Fontanellas A; Ávila MA; Arranz E; Enríquez de Salamanca R; Morales-Conejo M
    J Inherit Metab Dis; 2021 Jul; 44(4):790-791. PubMed ID: 34145602
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran.
    Ventura P; Sardh E; Longo N; Balwani M; Plutzky J; Gouya L; Phillips J; Rhyee S; Fanelli MJ; Sweetser MT; Petrides PE
    Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):879-894. PubMed ID: 35929959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing hyperhomocysteinemia using vitamin B
    Redonnet-Vernhet I; Mercié P; Lebreton L; Blouin JM; Bronnimann D; Mesli S; Guibet C; Ribeiro E; Gensous N; Duffau P; Gouya L; Richard E
    Mol Genet Metab Rep; 2024 Jun; 39():101076. PubMed ID: 38601120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria].
    Stölzel U
    Z Gastroenterol; 2020 Aug; 58(8):785. PubMed ID: 32785915
    [No Abstract]   [Full Text] [Related]  

  • 12. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
    Sardh E; Harper P
    J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New therapeutic option for acute hepatic porphyrias].
    Stölzel U; Schuppan D
    Dtsch Med Wochenschr; 2021 Aug; 146(15):955-958. PubMed ID: 34344029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?
    Ventura P; Corradini E; Di Pierro E; Marchini S; Marcacci M; Cuoghi C; Buzzetti E; Pietrangelo A
    Eur J Intern Med; 2020 Sep; 79():101-107. PubMed ID: 32487371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Givosiran to treat acute porphyria.
    Honor A; Rudnick SR; Bonkovsky HL
    Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
    Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E;
    Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved
    Li J; Liu J; Zhang X; Clausen V; Tran C; Arciprete M; Wang Q; Rocca C; Guan LH; Zhang G; Najarian D; Xu Y; Smith P; Wu JT; Chong S
    Drug Metab Dispos; 2021 Jul; 49(7):572-580. PubMed ID: 33941543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Givosiran: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
    Vassiliou D; Sardh E; Harper P; Simon AR; Clausen VA; Najafian N; Robbie GJ; Agarwal S
    Clin Pharmacol Ther; 2021 Nov; 110(5):1250-1260. PubMed ID: 34510420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta-synthase.
    Vassiliou D; Sardh E
    J Intern Med; 2021 Oct; 290(4):928-930. PubMed ID: 34184789
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.